- [Home](/) › - [ClinicalTrialStartPulse](/v/clinicaltrialstartpulse) › - [Hubs](/hub/clinicaltrialstartpulse) › - [All record reports](/hub/clinicaltrialstartpulse/records) › - Page 5 # ClinicalTrialStartPulse: all 1,000 record reports, page 5 of 5 Every ClinicalTrialStartPulse record report, 200 per page, grouped by state. Records 801 to 1,000: Janssen Research & Development, LLC: Phase 3 study closed enrollment, 813 enrolled (Arthritis, Psoriatic) to Yale University: Not applicable (device, behavioral) study in Readmission, Readmission Rates (800 participants). Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2. [1](/hub/clinicaltrialstartpulse/records) [2](/hub/clinicaltrialstartpulse/records/2) [3](/hub/clinicaltrialstartpulse/records/3) [4](/hub/clinicaltrialstartpulse/records/4) 5 ## US - [Janssen Research & Development, LLC: Phase 3 study closed enrollment, 813 enrolled (Arthritis, Psoriatic)](/report/clinicaltrialstartpulse/janssen-research-and-development-llc-us--nct-nct06807424-enrollment) - [Janssen Research & Development, LLC: Phase 3 study closed enrollment, 864 enrolled (Multiple Myeloma)](/report/clinicaltrialstartpulse/janssen-research-and-development-llc-us--nct-nct05455320-enrollment) - [Janssen Research & Development, LLC: Phase 3 study closed enrollment, 896 enrolled (Colitis, Ulcerative)](/report/clinicaltrialstartpulse/janssen-research-and-development-llc-us--nct-nct07196748-enrollment) - [Janssen Research & Development, LLC: Phase 3 study in Prostatic Neoplasms (400 participants)](/report/clinicaltrialstartpulse/janssen-research-and-development-llc-us--nct-nct07906717) - [Janssen Research & Development, LLC: Phase 4 study closed enrollment, 411 enrolled (Arthritis, Psoriatic)](/report/clinicaltrialstartpulse/janssen-research-and-development-llc-us--nct-nct04929210-enrollment) - [Janssen Scientific Affairs, LLC: Observational study closed enrollment, 21190 enrolled (Psoriasis)](/report/clinicaltrialstartpulse/janssen-scientific-affairs-llc-us--nct-nct00508547-enrollment) - [Johns Hopkins Bloomberg School of Public Health: Not applicable (device, behavioral) study in Food Choices (450 participants)](/report/clinicaltrialstartpulse/johns-hopkins-bloomberg-school-of-public-health-us--nct-nct07910604) - [Johns Hopkins Bloomberg School of Public Health: Not applicable (device, behavioral) study in Food Choices (450 participants)](/report/clinicaltrialstartpulse/johns-hopkins-bloomberg-school-of-public-health-us--nct-nct07910617) - [Johns Hopkins Bloomberg School of Public Health: Not applicable (device, behavioral) study in Ultra-processed Labels (12400 participants)](/report/clinicaltrialstartpulse/johns-hopkins-bloomberg-school-of-public-health-us--nct-nct07863570) - [Kailera: Phase 3 study closed enrollment, 1270 enrolled (Obesity With Diabetes, Overweight With Diabetes)](/report/clinicaltrialstartpulse/kailera-us--nct-nct07284901-enrollment) - [Kailera: Phase 3 study closed enrollment, 1270 enrolled (Obesity)](/report/clinicaltrialstartpulse/kailera-us--nct-nct07284979-enrollment) - [Kailera: Phase 3 study closed enrollment, 2530 enrolled (Obesity, Overweight)](/report/clinicaltrialstartpulse/kailera-us--nct-nct07284875-enrollment) - [Kardium Inc.: Observational study started recruiting, 500 planned (Atrial Fibrillation)](/report/clinicaltrialstartpulse/kardium-inc-us--nct-nct07651852-recruiting) - [Klein Buendel, Inc.: Not applicable (device, behavioral) study closed enrollment, 1796 enrolled (Cancer)](/report/clinicaltrialstartpulse/klein-buendel-inc-us--nct-nct05618158-enrollment) - [Lahey Clinic: Not applicable (device, behavioral) study closed enrollment, 662 enrolled (Lumbar Spondylolisthesis, Grade 1 Spondylolisthesis)](/report/clinicaltrialstartpulse/lahey-clinic-us--nct-nct03570801-enrollment) - [Lumicell, Inc.: Observational study started recruiting, 1500 planned (Breast Cancer)](/report/clinicaltrialstartpulse/lumicell-inc-us--nct-nct07616856-recruiting) - [Lumicell, Inc.: Observational study started recruiting, 1500 planned (Hypersensitivity Reactions)](/report/clinicaltrialstartpulse/lumicell-inc-us--nct-nct07572162-recruiting) - [M.D. Anderson Cancer Center: Early phase 1 study closed enrollment, 630 enrolled (Smoking Cessation)](/report/clinicaltrialstartpulse/m-d-anderson-cancer-center-us--nct-nct03059940-enrollment) - [M.D. Anderson Cancer Center: Not applicable (device, behavioral) study closed enrollment, 406 enrolled (Advanced Malignant Neoplasm, Caregiver)](/report/clinicaltrialstartpulse/m-d-anderson-cancer-center-us--nct-nct03671226-enrollment) - [M.D. Anderson Cancer Center: Not applicable (device, behavioral) study closed enrollment, 460 enrolled (Obesity-Related Malignant Neoplasm)](/report/clinicaltrialstartpulse/m-d-anderson-cancer-center-us--nct-nct05053113-enrollment) - [M.D. Anderson Cancer Center: Not applicable (device, behavioral) study closed enrollment, 479 enrolled (Cancer, Aging)](/report/clinicaltrialstartpulse/m-d-anderson-cancer-center-us--nct-nct05436327-enrollment) - [M.D. Anderson Cancer Center: Observational study closed enrollment, 450 enrolled (Head and Neck Carcinoma)](/report/clinicaltrialstartpulse/m-d-anderson-cancer-center-us--nct-nct01627093-enrollment) - [M.D. Anderson Cancer Center: Observational study closed enrollment, 818 enrolled (Colon Adenocarcinoma, Colorectal Carcinoma)](/report/clinicaltrialstartpulse/m-d-anderson-cancer-center-us--nct-nct02863107-enrollment) - [M.D. Anderson Cancer Center: Observational study in Data Collection, Sickle Cell Disease (500 participants)](/report/clinicaltrialstartpulse/m-d-anderson-cancer-center-us--nct-nct07911618) - [M.D. Anderson Cancer Center: Phase 3 study closed enrollment, 681 enrolled (Breast Cancer)](/report/clinicaltrialstartpulse/m-d-anderson-cancer-center-us--nct-nct01202851-enrollment) - [MacroGenics: Phase 1 study started recruiting, 314 planned (Urothelial Cancer, GastroEsophageal Cancer)](/report/clinicaltrialstartpulse/macrogenics-us--nct-nct07822399-recruiting) - [Massachusetts General Hospital: Not applicable (device, behavioral) study in Elevated Caregiver Strain, Dementia Caregiver (450 participants)](/report/clinicaltrialstartpulse/massachusetts-general-hospital-us--nct-nct07868588) - [Massachusetts General Hospital: Observational study in End Stage Renal Disease (ESRD), Volume Overload (400 participants)](/report/clinicaltrialstartpulse/massachusetts-general-hospital-us--nct-nct07866872) - [Mayo Clinic: Not applicable (device, behavioral) study closed enrollment, 680 enrolled (Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm)](/report/clinicaltrialstartpulse/mayo-clinic-us--nct-nct06198010-enrollment) - [Mayo Clinic: Not applicable (device, behavioral) study in Ostomy (500 participants)](/report/clinicaltrialstartpulse/mayo-clinic-us--nct-nct07879872) - [Medical University of South Carolina: Not applicable (device, behavioral) study closed enrollment, 10469 enrolled (Mental Health Issue, Substance Use Disorders)](/report/clinicaltrialstartpulse/medical-university-of-south-carolina-us--nct-nct05764213-enrollment) - [Medtronic Cardiac Ablation Solutions: Observational study closed enrollment, 393 enrolled (Persistent Atrial Fibrillation)](/report/clinicaltrialstartpulse/medtronic-cardiac-ablation-solutions-us--nct-nct05005949-enrollment) - [Medtronic MiniMed, Inc.: Not applicable (device, behavioral) study in Type 1 Diabetes, Type 2 Diabetes (1500 participants)](/report/clinicaltrialstartpulse/medtronic-minimed-inc-us--nct-nct07864168) - [Memorial Sloan Kettering Cancer Center: Not applicable (device, behavioral) study closed enrollment, 324 enrolled (Head and Neck Cancer, Head and Neck Tumor)](/report/clinicaltrialstartpulse/memorial-sloan-kettering-cancer-center-us--nct-nct05053230-enrollment) - [Memorial Sloan Kettering Cancer Center: Not applicable (device, behavioral) study closed enrollment, 360 enrolled (Chronic Pain, Musculoskeletal Pain)](/report/clinicaltrialstartpulse/memorial-sloan-kettering-cancer-center-us--nct-nct02979574-enrollment) - [Memorial Sloan Kettering Cancer Center: Observational study closed enrollment, 1047 enrolled (Ovarian Cancer, Prostate Cancer)](/report/clinicaltrialstartpulse/memorial-sloan-kettering-cancer-center-us--nct-nct02917798-enrollment) - [Memorial Sloan Kettering Cancer Center: Observational study closed enrollment, 338 enrolled (Multiple Ground Glass Opacities (GGOs))](/report/clinicaltrialstartpulse/memorial-sloan-kettering-cancer-center-us--nct-nct03802981-enrollment) - [Memorial Sloan Kettering Cancer Center: Observational study closed enrollment, 441 enrolled (Breast Cancer Survivors)](/report/clinicaltrialstartpulse/memorial-sloan-kettering-cancer-center-us--nct-nct03674437-enrollment) - [Memorial Sloan Kettering Cancer Center: Observational study closed enrollment, 501 enrolled (B-cell Non-Hodgkin Lymphoma, Aggressive)](/report/clinicaltrialstartpulse/memorial-sloan-kettering-cancer-center-us--nct-nct02633111-enrollment) - [Memorial Sloan Kettering Cancer Center: Phase 3 study in Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin (14000 participants)](/report/clinicaltrialstartpulse/memorial-sloan-kettering-cancer-center-us--nct-nct07890415) - [Memorial Sloan Kettering Cancer Center: Phase 4 study closed enrollment, 807 enrolled (Smoking Cessation)](/report/clinicaltrialstartpulse/memorial-sloan-kettering-cancer-center-us--nct-nct03315910-enrollment) - [Mentor Worldwide, LLC: Not applicable (device, behavioral) study closed enrollment, 3603 enrolled (Primary Breast Augmentation, Primary Breast Reconstruction)](/report/clinicaltrialstartpulse/mentor-worldwide-llc-us--nct-nct02919592-enrollment) - [Mentor Worldwide, LLC: Not applicable (device, behavioral) study closed enrollment, 400 enrolled (Breast Reconstruction, Revision Breast Reconstruction)](/report/clinicaltrialstartpulse/mentor-worldwide-llc-us--nct-nct02724371-enrollment) - [Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany: Phase 2 study closed enrollment, 381 enrolled (Systemic Lupus Erythematosus)](/report/clinicaltrialstartpulse/merck-healthcare-kgaa-darmstadt-germany-an-affiliate-of-us--nct-nct05540327-enrollment) - [Merck Sharp & Dohme LLC: Phase 3 study closed enrollment, 473 enrolled (Gastroesophageal Cancer)](/report/clinicaltrialstartpulse/merck-sharp-and-dohme-llc-us--nct-nct06356311-enrollment) - [Merck Sharp & Dohme LLC: Phase 3 study closed enrollment, 6033 enrolled (Papillomavirus Infections)](/report/clinicaltrialstartpulse/merck-sharp-and-dohme-llc-us--nct-nct04199689-enrollment) - [Merck Sharp & Dohme LLC: Phase 3 study started recruiting, 1104 planned (Diabetic Retinopathy, Macular Edema)](/report/clinicaltrialstartpulse/merck-sharp-and-dohme-llc-us--nct-nct07705607-recruiting) - [Merck Sharp & Dohme LLC: Phase 3 study started recruiting, 646 planned (Ovarian Cancer, Peritoneal Cancer)](/report/clinicaltrialstartpulse/merck-sharp-and-dohme-llc-us--nct-nct07743164-recruiting) - [Merck Sharp & Dohme LLC: Phase 3 study started recruiting, 802 planned (Ovarian Cancer, Ovarian Neoplasms)](/report/clinicaltrialstartpulse/merck-sharp-and-dohme-llc-us--nct-nct07776691-recruiting) - [Mercy BioAnalytics, Inc.: Not applicable (device, behavioral) study in Ovarian Cancer (1750 participants)](/report/clinicaltrialstartpulse/mercy-bioanalytics-inc-us--nct-nct07872644) - [Merz Therapeutics GmbH: Phase 3 study closed enrollment, 808 enrolled (Chronic Migraine)](/report/clinicaltrialstartpulse/merz-therapeutics-gmbh-us--nct-nct07018713-enrollment) - [Merz Therapeutics GmbH: Phase 3 study closed enrollment, 997 enrolled (Episodic Migraine)](/report/clinicaltrialstartpulse/merz-therapeutics-gmbh-us--nct-nct07018700-enrollment) - [Miami University: Not applicable (device, behavioral) study in Depression - Major Depressive Disorder, Psychological Distress (330 participants)](/report/clinicaltrialstartpulse/miami-university-us--nct-nct07889908) - [Michigan State University: Not applicable (device, behavioral) study closed enrollment, 935 enrolled (Obesity, Adolescent)](/report/clinicaltrialstartpulse/michigan-state-university-us--nct-nct04213014-enrollment) - [Milton S. Hershey Medical Center: Not applicable (device, behavioral) study closed enrollment, 702 enrolled (Walking, Difficulty, Mobility Limitation)](/report/clinicaltrialstartpulse/milton-s-hershey-medical-center-us--nct-nct05725564-enrollment) - [ModernaTX, Inc.: Phase 1 study completed, 482 enrolled (Epstein-Barr Virus Infection)](/report/clinicaltrialstartpulse/modernatx-inc-us--nct-nct05831111-completed) - [ModernaTX, Inc.: Phase 2 study completed, 1407 enrolled (Norovirus Acute Gastroenteritis)](/report/clinicaltrialstartpulse/modernatx-inc-us--nct-nct05992935-completed) - [ModernaTX, Inc.: Phase 4 study in SARS-CoV-2 (600 participants)](/report/clinicaltrialstartpulse/modernatx-inc-us--nct-nct07863635) - [Montefiore Medical Center: Not applicable (device, behavioral) study started recruiting, 338 planned (Cesarean Scar Defect)](/report/clinicaltrialstartpulse/montefiore-medical-center-us--nct-nct07634679-recruiting) - [Multitude Therapeutics Inc.: Phase 3 study started recruiting, 512 planned (NSCLC (Advanced Non-small Cell Lung Cancer))](/report/clinicaltrialstartpulse/multitude-therapeutics-inc-us--nct-nct07718737-recruiting) - [National Cancer Institute (NCI): Observational study closed enrollment, 500 enrolled (Macrophage Activation Syndrome, Primary Hemophagocytic Lymphohistiocytosis)](/report/clinicaltrialstartpulse/national-cancer-institute-nci-us--nct-nct03827343-enrollment) - [National Cancer Institute (NCI): Phase 2 study closed enrollment, 385 enrolled (Prostate Neoplasms, Prostatic Cancer)](/report/clinicaltrialstartpulse/national-cancer-institute-nci-us--nct-nct03181867-enrollment) - [National Institute of Allergy and Infectious Diseases (NIAID): Observational study in Anosmia, Chronic Obstructive Pulmonary Disease (350 participants)](/report/clinicaltrialstartpulse/national-institute-of-allergy-and-infectious-diseases-niaid-us--nct-nct07867184) - [National Institute of Allergy and Infectious Diseases (NIAID): Phase 3 study in Post-acute COVID-19 Syndrome (1300 participants)](/report/clinicaltrialstartpulse/national-institute-of-allergy-and-infectious-diseases-niaid-us--nct-nct07916259) - [National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS): Observational study closed enrollment, 521292 enrolled (Rheumatoid Arthritis, Ankylosing Spondylitis)](/report/clinicaltrialstartpulse/national-institute-of-arthritis-and-musculoskeletal-and-us--nct-nct02281747-enrollment) - [National Institute of Mental Health (NIMH): Observational study in Neuropsychiatric Disorders, Neuroinflammatory Disorders (5000 participants)](/report/clinicaltrialstartpulse/national-institute-of-mental-health-nimh-us--nct-nct07877246) - [National Institutes of Health Clinical Center (CC): Observational study closed enrollment, 144625 enrolled (Radiology Information Systems)](/report/clinicaltrialstartpulse/national-institutes-of-health-clinical-center-cc-us--nct-nct04579237-enrollment) - [National Institutes of Health Clinical Center (CC): Observational study in Blood Donors, Apheresis (5000 participants)](/report/clinicaltrialstartpulse/national-institutes-of-health-clinical-center-cc-us--nct-nct07877259) - [National Institutes of Health Clinical Center (CC): Observational study started recruiting, 1000 planned (Pulmonary Hypertension)](/report/clinicaltrialstartpulse/national-institutes-of-health-clinical-center-cc-us--nct-nct07647549-recruiting) - [National Institutes of Health Clinical Center (CC): Phase 2 study closed enrollment, 622 enrolled (Hemochromatosis)](/report/clinicaltrialstartpulse/national-institutes-of-health-clinical-center-cc-us--nct-nct00007150-enrollment) - [Northwestern University: Not applicable (device, behavioral) study closed enrollment, 57589 enrolled (Dementia, Cognitive Impairment)](/report/clinicaltrialstartpulse/northwestern-university-us--nct-nct05607732-enrollment) - [Northwestern University: Not applicable (device, behavioral) study in Perinatal Mental Health, Fathers (624 participants)](/report/clinicaltrialstartpulse/northwestern-university-us--nct-nct07893210) - [Novavax: Phase 4 study terminated, 6500 enrolled (COVID-19, Sars-CoV-2 Infection)](/report/clinicaltrialstartpulse/novavax-us--nct-nct07086222-terminated) - [Novo Nordisk A/S: Phase 3 study closed enrollment, 1205 enrolled (Non-alcoholic Steatohepatitis)](/report/clinicaltrialstartpulse/novo-nordisk-a-s-us--nct-nct04822181-enrollment) - [Novo Nordisk A/S: Phase 3 study in Cardiovascular Risk, Obesity (8500 participants)](/report/clinicaltrialstartpulse/novo-nordisk-a-s-us--nct-nct07861100) - [NRG Oncology: Phase 3 study closed enrollment, 475 enrolled (Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma)](/report/clinicaltrialstartpulse/nrg-oncology-us--nct-nct05050162-enrollment) - [NYU Langone Health: Not applicable (device, behavioral) study closed enrollment, 486 enrolled (Healthy, Family Research)](/report/clinicaltrialstartpulse/nyu-langone-health-us--nct-nct03945552-enrollment) - [NYU Langone Health: Not applicable (device, behavioral) study in Atherosclerotic Cardiovascular Disease (7501 participants)](/report/clinicaltrialstartpulse/nyu-langone-health-us--nct-nct07914777) - [NYU Langone Health: Not applicable (device, behavioral) study in Cardiovascular Diseases (1050 participants)](/report/clinicaltrialstartpulse/nyu-langone-health-us--nct-nct07909395) - [NYU Langone Health: Phase 2 study in Adenotonsillectomy, Postoperative Pain (500 participants)](/report/clinicaltrialstartpulse/nyu-langone-health-us--nct-nct07870447) - [Ohio State University: Not applicable (device, behavioral) study completed, 348 enrolled (Cardiometabolic Syndrome, Physical Inactivity)](/report/clinicaltrialstartpulse/ohio-state-university-us--nct-nct06055036-completed) - [Ohio State University: Observational study in Substance Use Disorder (SUD), Opioid Use Disorder (1200 participants)](/report/clinicaltrialstartpulse/ohio-state-university-us--nct-nct07875361) - [Ohio State University: Phase 2 study in Caregiver Burden, Caregiver Burnout (344 participants)](/report/clinicaltrialstartpulse/ohio-state-university-us--nct-nct07868718) - [Otsuka Pharmaceutical Development & Commercialization, Inc.: Phase 3 study closed enrollment, 538 enrolled (Schizophrenia)](/report/clinicaltrialstartpulse/otsuka-pharmaceutical-development-and-commercialization-inc-us--nct-nct06894212-enrollment) - [Otsuka Pharmaceutical Development & Commercialization, Inc.: Phase 3 study started recruiting, 1120 planned (Generalized Anxiety Disorder)](/report/clinicaltrialstartpulse/otsuka-pharmaceutical-development-and-commercialization-inc-us--nct-nct07786454-recruiting) - [Ouraring Inc.: Observational study in Trying to Conceive (50000 participants)](/report/clinicaltrialstartpulse/ouraring-inc-us--nct-nct07862829) - [Pacific Institute for Research and Evaluation: Not applicable (device, behavioral) study in Implementation Strategies (1320 participants)](/report/clinicaltrialstartpulse/pacific-institute-for-research-and-evaluation-us--nct-nct07904078) - [Pelage Pharmaceuticals, Inc.: Phase 3 study started recruiting, 600 planned (Androgenetic Alopecia)](/report/clinicaltrialstartpulse/pelage-pharmaceuticals-inc-us--nct-nct07819435-recruiting) - [Penn State University: Not applicable (device, behavioral) study in COVID-19 Vaccination (1064 participants)](/report/clinicaltrialstartpulse/penn-state-university-us--nct-nct07861087) - [Pfizer: Observational study closed enrollment, 846279 enrolled (Community-Acquired Pneumonia (CAP))](/report/clinicaltrialstartpulse/pfizer-us--nct-nct07251465-enrollment) - [Pfizer: Phase 2 study closed enrollment, 507 enrolled (Atopic Dermatitis)](/report/clinicaltrialstartpulse/pfizer-us--nct-nct05995964-enrollment) - [Pfizer: Phase 2 study closed enrollment, 605 enrolled (Pneumococcal Disease)](/report/clinicaltrialstartpulse/pfizer-us--nct-nct06524414-enrollment) - [Pfizer: Phase 2 study closed enrollment, 940 enrolled (Overweight, Obesity)](/report/clinicaltrialstartpulse/pfizer-us--nct-nct07575932-enrollment) - [Pfizer: Phase 3 study closed enrollment, 1035 enrolled (Breast Cancer)](/report/clinicaltrialstartpulse/pfizer-us--nct-nct06760637-enrollment) - [Pfizer: Phase 3 study closed enrollment, 1078 enrolled (Obesity, Overweight and/or Obesity)](/report/clinicaltrialstartpulse/pfizer-us--nct-nct07400653-enrollment) - [Pfizer: Phase 3 study closed enrollment, 1571 enrolled (Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo)](/report/clinicaltrialstartpulse/pfizer-us--nct-nct06072183-enrollment) - [Pfizer: Phase 3 study closed enrollment, 3578 enrolled (Obesity and Overweight)](/report/clinicaltrialstartpulse/pfizer-us--nct-nct07311850-enrollment) - [Pfizer: Phase 3 study closed enrollment, 609 enrolled (Metastatic Castrate Resistant Prostate Cancer (mCRPC))](/report/clinicaltrialstartpulse/pfizer-us--nct-nct06551324-enrollment) - [Pfizer: Phase 3 study closed enrollment, 896 enrolled (Ulcerative Colitis)](/report/clinicaltrialstartpulse/pfizer-us--nct-nct03950232-enrollment) - [Pfizer: Phase 3 study in Asthma (1100 participants)](/report/clinicaltrialstartpulse/pfizer-us--nct-nct07869043) - [Pfizer: Phase 3 study in Obesity, Overweight and/or Obesity (756 participants)](/report/clinicaltrialstartpulse/pfizer-us--nct-nct07915609) - [Phathom Pharmaceuticals, Inc.: Phase 3 study started recruiting, 500 planned (Symptomatic Non-erosive Gastroesophageal Reflux Disease)](/report/clinicaltrialstartpulse/phathom-pharmaceuticals-inc-us--nct-nct07752407-recruiting) - [Philips Digital & Computational Pathology: Observational study in Pathological Processes (470 participants)](/report/clinicaltrialstartpulse/philips-digital-and-computational-pathology-us--nct-nct07881874) - [Radnet Management, Inc.: Observational study in Metabolic Dysfunction-steatohepatitis (MASH) (524 participants)](/report/clinicaltrialstartpulse/radnet-management-inc-us--nct-nct07860814) - [RAI Services Company: Not applicable (device, behavioral) study in Smoking, Tobacco (480 participants)](/report/clinicaltrialstartpulse/rai-services-company-us--nct-nct07879638) - [RayzeBio, Inc.: Phase 3 study closed enrollment, 343 enrolled (GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor)](/report/clinicaltrialstartpulse/rayzebio-inc-us--nct-nct05477576-enrollment) - [Reckitt Benckiser Healthcare (UK) Limited: Observational study in Muscle Soreness (600 participants)](/report/clinicaltrialstartpulse/reckitt-benckiser-healthcare-uk-limited-us--nct-nct07873242) - [Restor3D: Observational study started recruiting, 2250 planned (Joint Replacement, Arthropathy)](/report/clinicaltrialstartpulse/restor3d-us--nct-nct07563803-recruiting) - [Rochester General Hospital: Observational study closed enrollment, 1320 enrolled (Nasopharyngeal Colonization and Acute Otitis Media)](/report/clinicaltrialstartpulse/rochester-general-hospital-us--nct-nct02591563-enrollment) - [Roswell Park Cancer Institute: Not applicable (device, behavioral) study in Cigarette Smoking-Related Carcinoma (600 participants)](/report/clinicaltrialstartpulse/roswell-park-cancer-institute-us--nct-nct07857681) - [Sagimet Biosciences Inc.: Phase 3 study in Acne Vulgaris (800 participants)](/report/clinicaltrialstartpulse/sagimet-biosciences-inc-us--nct-nct07863193) - [SalivIQ Diagnostics, Inc.: Observational study in Streptococcal Pharyngitis, Group A Streptococcal Infection (668 participants)](/report/clinicaltrialstartpulse/saliviq-diagnostics-inc-us--nct-nct07891728) - [Sanofi: Observational study completed, 4878935 enrolled (Chlamydial Infections)](/report/clinicaltrialstartpulse/sanofi-us--nct-nct07094373-completed) - [Sanofi: Phase 3 study closed enrollment, 1856 enrolled (Dermatitis Atopic)](/report/clinicaltrialstartpulse/sanofi-us--nct-nct05492578-enrollment) - [Sanofi: Phase 3 study closed enrollment, 464 enrolled (Dermatitis Atopic)](/report/clinicaltrialstartpulse/sanofi-us--nct-nct06241118-enrollment) - [Sanofi: Phase 4 study in COVID-19 (660 participants)](/report/clinicaltrialstartpulse/sanofi-us--nct-nct07861542) - [Schweitzer Engineering Laboratories: Observational study in Autism Spectrum Disorder (330 participants)](/report/clinicaltrialstartpulse/schweitzer-engineering-laboratories-us--nct-nct07903675) - [Shionogi: Phase 3 study started recruiting, 2000 planned (SARS-CoV-2)](/report/clinicaltrialstartpulse/shionogi-us--nct-nct07743580-recruiting) - [Smith & Nephew, Inc.: Observational study started recruiting, 1000 planned (Knee Injuries, Joint Surface Knee Lesions)](/report/clinicaltrialstartpulse/smith-and-nephew-inc-us--nct-nct07786207-recruiting) - [St. Jude Children's Research Hospital: Not applicable (device, behavioral) study in Stigma (2980 participants)](/report/clinicaltrialstartpulse/st-jude-children-s-research-hospital-us--nct-nct07882927) - [Stanford University: Not applicable (device, behavioral) study in Shared Decision-making (600 participants)](/report/clinicaltrialstartpulse/stanford-university-us--nct-nct07913204) - [Stanford University: Not applicable (device, behavioral) study started recruiting, 3000 planned (Colorectal Cancer Screening)](/report/clinicaltrialstartpulse/stanford-university-us--nct-nct07522177-recruiting) - [Stanford University: Not applicable (device, behavioral) study started recruiting, 750 planned (Alcohol Misuse)](/report/clinicaltrialstartpulse/stanford-university-us--nct-nct07661563-recruiting) - [Stemline Therapeutics, Inc.: Phase 3 study closed enrollment, 4556 enrolled (Breast Cancer)](/report/clinicaltrialstartpulse/stemline-therapeutics-inc-us--nct-nct06492616-enrollment) - [SWOG Cancer Research Network: Phase 3 study closed enrollment, 354 enrolled (Colorectal Neoplasms)](/report/clinicaltrialstartpulse/swog-cancer-research-network-us--nct-nct01349881-enrollment) - [SystImmune Inc.: Phase 1 study in Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors (424 participants)](/report/clinicaltrialstartpulse/systimmune-inc-us--nct-nct07857616) - [SystImmune Inc.: Phase 3 study in Urothelial Cancer, Metastatic Urothelial Cancer (520 participants)](/report/clinicaltrialstartpulse/systimmune-inc-us--nct-nct07869836) - [Takeda: Phase 2 study completed, 324 enrolled (Carcinoma, Non-Small-Cell Lung)](/report/clinicaltrialstartpulse/takeda-us--nct-nct02716116-completed) - [Takeda: Phase 3 study closed enrollment, 601 enrolled (Psoriatic Arthritis)](/report/clinicaltrialstartpulse/takeda-us--nct-nct06671496-enrollment) - [Takeda: Phase 3 study completed, 354 enrolled (Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC))](/report/clinicaltrialstartpulse/takeda-us--nct-nct04129502-completed) - [Teva Branded Pharmaceutical Products R&D LLC: Phase 2 study closed enrollment, 349 enrolled (Multiple System Atrophy)](/report/clinicaltrialstartpulse/teva-branded-pharmaceutical-products-r-and-d-llc-us--nct-nct06568237-enrollment) - [Teva Branded Pharmaceutical Products R&D LLC: Phase 3 study closed enrollment, 2769 enrolled (Asthma)](/report/clinicaltrialstartpulse/teva-branded-pharmaceutical-products-r-and-d-llc-us--nct-nct06052267-enrollment) - [Teva Branded Pharmaceutical Products R&D LLC: Phase 3 study closed enrollment, 649 enrolled (Asthma)](/report/clinicaltrialstartpulse/teva-branded-pharmaceutical-products-r-and-d-llc-us--nct-nct06664619-enrollment) - [Teva Branded Pharmaceutical Products R&D LLC: Phase 3 study completed, 649 enrolled (Asthma)](/report/clinicaltrialstartpulse/teva-branded-pharmaceutical-products-r-and-d-llc-us--nct-nct06664619-completed) - [The University of Texas Health Science Center, Houston: Not applicable (device, behavioral) study in Allergic Contact Dermatitis (ACD) (350 participants)](/report/clinicaltrialstartpulse/the-university-of-texas-health-science-center-houston-us--nct-nct07868900) - [The University of Texas Health Science Center, Houston: Not applicable (device, behavioral) study started recruiting, 350 planned (Physical Activity)](/report/clinicaltrialstartpulse/the-university-of-texas-health-science-center-houston-us--nct-nct07541118-recruiting) - [TriGemX Bio, Inc.: Phase 3 study started recruiting, 1500 planned (Migraine)](/report/clinicaltrialstartpulse/trigemx-bio-inc-us--nct-nct07816367-recruiting) - [UNC Lineberger Comprehensive Cancer Center: Not applicable (device, behavioral) study started recruiting, 395 planned (Cancer)](/report/clinicaltrialstartpulse/unc-lineberger-comprehensive-cancer-center-us--nct-nct07788339-recruiting) - [University College, London: Observational study in Inherited Retinal Degeneration Associated With RPGR Mutations, Inherited Retinal Degeneration Associated With Biallelic RPE65 Mutations (4887 participants)](/report/clinicaltrialstartpulse/university-college-london-us--nct-nct07901907) - [University of Alabama at Birmingham: Not applicable (device, behavioral) study closed enrollment, 400 enrolled (Pregnancy Complications, Maternal Distress)](/report/clinicaltrialstartpulse/university-of-alabama-at-birmingham-us--nct-nct06510075-enrollment) - [University of Alabama at Birmingham: Not applicable (device, behavioral) study started recruiting, 2748 planned (Breast Cancer, Corpus Uteri Cancer)](/report/clinicaltrialstartpulse/university-of-alabama-at-birmingham-us--nct-nct07671937-recruiting) - [University of Arizona: Not applicable (device, behavioral) study completed, 15128 enrolled (Colorectal Cancer)](/report/clinicaltrialstartpulse/university-of-arizona-us--nct-nct06542835-completed) - [University of California, Irvine: Not applicable (device, behavioral) study closed enrollment, 1000 enrolled (Child Development, Brain Development)](/report/clinicaltrialstartpulse/university-of-california-irvine-us--nct-nct03593356-enrollment) - [University of California, San Francisco: Not applicable (device, behavioral) study closed enrollment, 1418 enrolled (Colon Cancer, Cancer Colorectal)](/report/clinicaltrialstartpulse/university-of-california-san-francisco-us--nct-nct06191185-enrollment) - [University of California, San Francisco: Not applicable (device, behavioral) study closed enrollment, 353 enrolled (Bladder Cancer, Breast Cancer)](/report/clinicaltrialstartpulse/university-of-california-san-francisco-us--nct-nct05056077-enrollment) - [University of California, San Francisco: Not applicable (device, behavioral) study completed, 456 enrolled (Insomnia, Depression)](/report/clinicaltrialstartpulse/university-of-california-san-francisco-us--nct-nct05596318-completed) - [University of California, San Francisco: Not applicable (device, behavioral) study in Inpatient Experience Survey Administration, Inpatient Experience Survey Response (21800 participants)](/report/clinicaltrialstartpulse/university-of-california-san-francisco-us--nct-nct07871136) - [University of Chicago: Not applicable (device, behavioral) study started recruiting, 330 planned (Alzheimer s Disease, Dementia)](/report/clinicaltrialstartpulse/university-of-chicago-us--nct-nct07346183-recruiting) - [University of Cologne: Not applicable (device, behavioral) study in Anxiety and Fear (400 participants)](/report/clinicaltrialstartpulse/university-of-cologne-us--nct-nct07860034) - [University of Illinois Chicago: Not applicable (device, behavioral) study completed, 636 enrolled (Depression)](/report/clinicaltrialstartpulse/university-of-illinois-chicago-us--nct-nct04290754-completed) - [University of Kansas Medical Center: Not applicable (device, behavioral) study completed, 410 enrolled (Weight Loss, Pediatric Obesity)](/report/clinicaltrialstartpulse/university-of-kansas-medical-center-us--nct-nct05612971-completed) - [University of Kansas Medical Center: Not applicable (device, behavioral) study completed, 582 enrolled (Obesity, Obesity, Morbid)](/report/clinicaltrialstartpulse/university-of-kansas-medical-center-us--nct-nct05710510-completed) - [University of Massachusetts, Worcester: Observational study in Cardiac Arrest, Out-Of-Hospital, Hypotension (1400 participants)](/report/clinicaltrialstartpulse/university-of-massachusetts-worcester-us--nct-nct07897370) - [University of Michigan: Not applicable (device, behavioral) study closed enrollment, 362 enrolled (Alcohol Use Disorder)](/report/clinicaltrialstartpulse/university-of-michigan-us--nct-nct05594238-enrollment) - [University of Michigan: Not applicable (device, behavioral) study in AI Companionship (1200 participants)](/report/clinicaltrialstartpulse/university-of-michigan-us--nct-nct07858279) - [University of Michigan: Observational study in Traumatic Brain Injury (500 participants)](/report/clinicaltrialstartpulse/university-of-michigan-us--nct-nct07858266) - [University of Nebraska: Observational study in Acute Kidney Injury, Delirium (25000 participants)](/report/clinicaltrialstartpulse/university-of-nebraska-us--nct-nct07866560) - [University of New Hampshire: Phase 2 study in Alcohol Misuse Prevention, Sexual Violence Prevention (350 participants)](/report/clinicaltrialstartpulse/university-of-new-hampshire-us--nct-nct07888153) - [University of Pennsylvania: Not applicable (device, behavioral) study closed enrollment, 317 enrolled (Obesity, Childhood)](/report/clinicaltrialstartpulse/university-of-pennsylvania-us--nct-nct05783765-enrollment) - [University of Pennsylvania: Not applicable (device, behavioral) study completed, 603 enrolled (Psoriasis, Psoriatic Arthritis)](/report/clinicaltrialstartpulse/university-of-pennsylvania-us--nct-nct05908240-completed) - [University of Pennsylvania: Not applicable (device, behavioral) study in Firearm Safety, Firearm Safety Storage (1858 participants)](/report/clinicaltrialstartpulse/university-of-pennsylvania-us--nct-nct07886983) - [University of Pennsylvania: Not applicable (device, behavioral) study in HIV, Hypertension (400 participants)](/report/clinicaltrialstartpulse/university-of-pennsylvania-us--nct-nct07862452) - [University of Pennsylvania: Not applicable (device, behavioral) study started recruiting, 4800 planned (Tobacco Use, Tobacco Use Cessation)](/report/clinicaltrialstartpulse/university-of-pennsylvania-us--nct-nct07735286-recruiting) - [University of Pennsylvania: Not applicable (device, behavioral) study terminated, 4000 enrolled (Patient Handoff, Healthcare Team)](/report/clinicaltrialstartpulse/university-of-pennsylvania-us--nct-nct04571749-terminated) - [University of Pittsburgh: Not applicable (device, behavioral) study closed enrollment, 765 enrolled (Suicide and Depression, Adolescent Behavior)](/report/clinicaltrialstartpulse/university-of-pittsburgh-us--nct-nct05748730-enrollment) - [University of Rochester: Not applicable (device, behavioral) study closed enrollment, 1175 enrolled (Depression, Insomnia)](/report/clinicaltrialstartpulse/university-of-rochester-us--nct-nct05456607-enrollment) - [University of South Carolina: Not applicable (device, behavioral) study started recruiting, 350 planned (Doula Support, Postpartum)](/report/clinicaltrialstartpulse/university-of-south-carolina-us--nct-nct07787845-recruiting) - [University of Texas at Austin: Not applicable (device, behavioral) study in Alcohol Use, Underage Drinking (440 participants)](/report/clinicaltrialstartpulse/university-of-texas-at-austin-us--nct-nct07869550) - [University of Utah: Not applicable (device, behavioral) study in Skin Cancer Prevention, Sun Safety (450 participants)](/report/clinicaltrialstartpulse/university-of-utah-us--nct-nct07904572) - [University of Utah: Not applicable (device, behavioral) study in Vaccine Confidence, Adolescent Vaccination (2000 participants)](/report/clinicaltrialstartpulse/university-of-utah-us--nct-nct07878442) - [University of Utah: Phase 3 study closed enrollment, 1455 enrolled (HPV Vaccination, Uptake Vaccination)](/report/clinicaltrialstartpulse/university-of-utah-us--nct-nct07217145-enrollment) - [University of Washington: Not applicable (device, behavioral) study completed, 345 enrolled (Alcohol Use, Posttraumatic Stress Disorder)](/report/clinicaltrialstartpulse/university-of-washington-us--nct-nct06648395-completed) - [University of Wisconsin, Madison: Not applicable (device, behavioral) study completed, 1529 enrolled (Well-Being, Psychological)](/report/clinicaltrialstartpulse/university-of-wisconsin-madison-us--nct-nct07051330-completed) - [University of Wisconsin, Madison: Not applicable (device, behavioral) study in Myopia, Astigmatism (333 participants)](/report/clinicaltrialstartpulse/university-of-wisconsin-madison-us--nct-nct07909720) - [University of Wisconsin, Madison: Not applicable (device, behavioral) study started recruiting, 1000 planned (Tick Bites)](/report/clinicaltrialstartpulse/university-of-wisconsin-madison-us--nct-nct07756606-recruiting) - [University of Wisconsin, Madison: Not applicable (device, behavioral) study started recruiting, 6900 planned (Diabetic Retinopathy, Diabetes Mellitus)](/report/clinicaltrialstartpulse/university-of-wisconsin-madison-us--nct-nct06763952-recruiting) - [University of Wisconsin, Madison: Observational study closed enrollment, 1545 enrolled (Sleep Disorders, Cerebrovascular Disorders)](/report/clinicaltrialstartpulse/university-of-wisconsin-madison-us--nct-nct00005557-enrollment) - [VA Office of Research and Development: Not applicable (device, behavioral) study closed enrollment, 368 enrolled (Suicide, Attempted, Suicidal Ideation)](/report/clinicaltrialstartpulse/va-office-of-research-and-development-us--nct-nct05256940-enrollment) - [VA Office of Research and Development: Not applicable (device, behavioral) study in Insomnia Disorder, Mild Traumatic Brain Injury (900 participants)](/report/clinicaltrialstartpulse/va-office-of-research-and-development-us--nct-nct07886398) - [VA Office of Research and Development: Not applicable (device, behavioral) study started recruiting, 310 planned (Gout, Gouty Arthritis)](/report/clinicaltrialstartpulse/va-office-of-research-and-development-us--nct-nct06887452-recruiting) - [VA Office of Research and Development: Phase 3 study closed enrollment, 378 enrolled (Prostate Cancer, Oligometastasis)](/report/clinicaltrialstartpulse/va-office-of-research-and-development-us--nct-nct04787744-enrollment) - [VA Office of Research and Development: Phase 3 study started recruiting, 1630 planned (Basal Cell Carcinoma)](/report/clinicaltrialstartpulse/va-office-of-research-and-development-us--nct-nct05212246-recruiting) - [Vanderbilt University Medical Center: Observational study closed enrollment, 377 enrolled (Sickle Cell Disease, Pulmonary Disease)](/report/clinicaltrialstartpulse/vanderbilt-university-medical-center-us--nct-nct05153967-enrollment) - [Vanderbilt University Medical Center: Observational study completed, 500 enrolled (Microbial Colonization, Eye Diseases)](/report/clinicaltrialstartpulse/vanderbilt-university-medical-center-us--nct-nct05414994-completed) - [Vanderbilt University Medical Center: Phase 4 study started recruiting, 2290 planned (Pain, Post Operative Analgesia)](/report/clinicaltrialstartpulse/vanderbilt-university-medical-center-us--nct-nct07224711-recruiting) - [Vaxcyte, Inc.: Phase 3 study closed enrollment, 1390 enrolled (Pneumococcal Disease)](/report/clinicaltrialstartpulse/vaxcyte-inc-us--nct-nct07365826-enrollment) - [Vaxcyte, Inc.: Phase 3 study completed, 4049 enrolled (Pneumococcal Disease)](/report/clinicaltrialstartpulse/vaxcyte-inc-us--nct-nct07284654-completed) - [Vertanical GmbH: Phase 3 study started recruiting, 810 planned (Lumbosacral Radiculopathy)](/report/clinicaltrialstartpulse/vertanical-gmbh-us--nct-nct06956014-recruiting) - [Viatris Innovation GmbH: Phase 3 study closed enrollment, 451 enrolled (Lupus Erythematosus, Systemic)](/report/clinicaltrialstartpulse/viatris-innovation-gmbh-us--nct-nct05672576-enrollment) - [Viatris Innovation GmbH: Phase 3 study closed enrollment, 470 enrolled (Lupus Erythematosus, Systemic)](/report/clinicaltrialstartpulse/viatris-innovation-gmbh-us--nct-nct05648500-enrollment) - [Virginia Commonwealth University: Observational study started recruiting, 1000 planned (DM1, Myotonic Dystrophy)](/report/clinicaltrialstartpulse/virginia-commonwealth-university-us--nct-nct07700225-recruiting) - [Wake Forest University Health Sciences: Not applicable (device, behavioral) study started recruiting, 600 planned (Congestive Heart Failure)](/report/clinicaltrialstartpulse/wake-forest-university-health-sciences-us--nct-nct07400042-recruiting) - [Wake Forest University Health Sciences: Phase 4 study in Hypotension During Surgery, Cesarean Birth (1500 participants)](/report/clinicaltrialstartpulse/wake-forest-university-health-sciences-us--nct-nct07900919) - [Washington State University: Not applicable (device, behavioral) study in Chronic Pain (400 participants)](/report/clinicaltrialstartpulse/washington-state-university-us--nct-nct07863375) - [Washington University School of Medicine: Not applicable (device, behavioral) study closed enrollment, 600 enrolled (HIV Prevention)](/report/clinicaltrialstartpulse/washington-university-school-of-medicine-us--nct-nct07002866-enrollment) - [Washington University School of Medicine: Not applicable (device, behavioral) study in Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder) (10000 participants)](/report/clinicaltrialstartpulse/washington-university-school-of-medicine-us--nct-nct07900893) - [Washington University School of Medicine: Not applicable (device, behavioral) study in SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder (325 participants)](/report/clinicaltrialstartpulse/washington-university-school-of-medicine-us--nct-nct07875790) - [Weill Medical College of Cornell University: Observational study closed enrollment, 1040 enrolled (Stem Cell Transplant Complications, Delirium)](/report/clinicaltrialstartpulse/weill-medical-college-of-cornell-university-us--nct-nct04937400-enrollment) - [Yale University: Not applicable (device, behavioral) study in Preventive Medicine, Hypertension (3680 participants)](/report/clinicaltrialstartpulse/yale-university-us--nct-nct07865247) - [Yale University: Not applicable (device, behavioral) study in Readmission, Readmission Rates (800 participants)](/report/clinicaltrialstartpulse/yale-university-us--nct-nct07890961) [1](/hub/clinicaltrialstartpulse/records) [2](/hub/clinicaltrialstartpulse/records/2) [3](/hub/clinicaltrialstartpulse/records/3) [4](/hub/clinicaltrialstartpulse/records/4) 5 [Browse ClinicalTrialStartPulse by category and location](/hub/clinicaltrialstartpulse) · [Search and filter ClinicalTrialStartPulse](/v/clinicaltrialstartpulse)